Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal
cancer

- Recurrent or persistent disease

- Meets 1 of the following criteria:

- Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1
dimension (longest dimension to be recorded) as ≥ 20 mm by chest x-ray OR as ≥
10 mm by spiral CT scan, MRI, or caliper measurement by clinical exam

- Must have ≥ 1 "target lesion" that can be used to assess response to study
treatment as defined by RECIST criteria

- Tumors within a previously irradiated field will be designated as
"non-target" lesions unless progression is documented or a biopsy is
obtained to confirm persistence ≥ 90 days following completion of
radiotherapy

- Lymph nodes must be ≥ 15 mm in short axis by CT scan or MRI

- Detectable disease, defined as non-measurable disease meeting ≥ 1 of the
following criteria:

- CA-125 ≥ 2 times upper limit of normal (ULN) at baseline

- Ascites and/or pleural effusion attributed to tumor

- Solid and/or cystic abnormalities on radiographic imaging that do not meet
RECIST criteria definitions for target lesions

- Must have received 1 prior platinum-based chemotherapeutic regimen that contained
carboplatin, cisplatin, or another organoplatinum compound for management of the
primary disease

- Initial treatment may have included intraperitoneal therapy, consolidation
therapy, non-cytotoxic therapy, or extended therapy administered after surgical
or non-surgical assessment

- Prior biologic (non-cytotoxic) therapy as part of the primary treatment regimen
allowed

- No prior non-cytotoxic therapy for management of recurrent or persistent
disease

- Two additional prior cytotoxic regimens for management of recurrent or
persistent disease allowed (≤ 1 non-platinum, non-taxane regimen allowed)

- Patients who have received only one prior cytotoxic regimen (i.e.,
platinum-based regimen for management of primary disease) must have a
platinum-free interval of < 12 months OR have progressed during platinum-based
therapy OR have persistent disease after platinum-based therapy

- Not eligible for a higher priority GOG clinical trial (i.e., any active phase III GOG
protocol or Rare Tumor protocol for the same patient population)

- No history or evidence of CNS disease by physical exam, including primary brain tumor
or brain metastases

PATIENT CHARACTERISTICS:

- GOG performance status (PS) 0-2 (for patients who have had 1 prior treatment)

- GOG PS 0-1 (for patients who have had 2 or 3 prior treatments)

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Creatinine ≤ 1.5 times ULN

- Bilirubin ≤ 1.5 times ULN

- SGOT ≤ 3.0 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

- PT/INR ≤ 1.5 (or an in-range INR, usually between 2 and 3, if the patient is on a
stable dose of therapeutic warfarin for management of deep vein thrombosis, including
pulmonary embolism)

- PTT ≤ 1.5 times ULN

- Fasting serum cholesterol ≤ 300 mg/dL (or ≤ 7.75 mmol/L) AND fasting triglycerides ≤
300 mg/dL (or ≤ 3.42 mmol/L)

- Urine protein:creatinine ratio < 1.0

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other invasive malignancies within the past 3 years except nonmelanoma skin cancer

- No clinically significant cardiovascular disease, including any of the following:

- Uncontrolled hypertension, defined as systolic BP > 150 mm Hg or diastolic BP >
90 mm Hg

- Myocardial infarction or unstable angina within the past 6 months

- NYHA class II-IV congestive heart failure

- Serious cardiac arrhythmia requiring medication (asymptomatic, atrial
fibrillation with controlled ventricular rate allowed)

- Ejection fraction < 50% in patients who received prior treatment with an
anthracycline (including doxorubicin hydrochloride and/or liposomal doxorubicin
hydrochloride)

- Peripheral vascular disease ≥ CTCAE grade 2 (i.e., at least brief [< 24 hours]
episodes of ischemia managed non-surgically and without permanent deficit)

- Cerebrovascular accident or transient ischemic attack within the past 6 months

- No acute hepatitis or active infection requiring parenteral antibiotics (except for
uncomplicated urinary tract infection)

- No history or evidence of seizures not controlled with standard medical therapy

- No subarachnoid hemorrhage within the past 6 months

- No active bleeding or pathologic condition that carries a high risk of bleeding
(e.g., known bleeding disorder, coagulopathy, or tumor involving major vessels)

- No abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess
within the past 28 days

- No clinical symptoms or signs of GI obstruction or requirement for parenteral
hydration and/or nutrition

- No serious non-healing wound, ulcer, or bone fracture

- No known hypersensitivity to murine or chimeric antibodies

- No other medical history or condition that, in the opinion of the investigator, would
preclude study participation

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from prior surgery, radiotherapy, or chemotherapy

- No prior everolimus or any other mTOR inhibitor

- No prior cancer treatment that would contraindicate study therapy

- No prior radiotherapy to any portion of the abdominal cavity or pelvis other than for
the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the
past 5 years

- Prior radiotherapy for localized cancer of the breast, head and neck, or skin
allowed provided it was completed > 3 years ago and the patient remains free of
recurrent or metastatic disease

- No prior chemotherapy for any abdominal or pelvic tumor other than for the treatment
of ovarian, fallopian tube, or primary peritoneal cancer within the past 5 years

- Prior adjuvant chemotherapy for localized breast cancer allowed provided it was
completed > 3 years ago and the patient remains free of recurrent or metastatic
disease

- For the purposes of this study, poly (ADP-ribose) polymerase (PARP) inhibitors will
be considered "cytotoxic," and prior treatment with PARP inhibitors for primary or
recurrent disease WILL be allowed (either alone or in combination with chemotherapy)

- At least 12 weeks since prior chimeric, human, or humanized monoclonal antibodies
(including bevacizumab) or VEGF receptor fusion protein (including aflibercept)

- More than 30 days since prior and no other concurrent investigational therapy

- More than 28 days since prior major surgery

- At least 3 weeks since any other prior therapy directed at the malignant tumor,
including biological or immunologic agents (small molecules or murine monoclonal
antibodies)

- At least 1 week since prior hormonal therapy directed at the malignant tumor

- No other concurrent anticancer agents

- No concurrent chronic treatment with systemic steroids or other immunosuppressive
agents

- Concurrent warfarin allowed for prophylaxis or treatment of thrombosis

- Concurrent low molecular weight heparin allowed provided PT/INR is ≤ 1.5

- Concurrent low-dose aspirin (≤ 325 mg/day) allowed for patients at a higher risk for
arterial thromboembolic disease